ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1 Following switch to...
Hence then, the article about new novartis data further support benefits of kesimpta in relapsing ms following switch from oral disease modifying therapies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies )
Also on site :
- In 1930, 3 Entrepreneurs Started a Toy Company During the Great Depression; Today, It’s a Household Name
- Karen Hale’s mother has lived with breast cancer for nearly 30 years; now the Hales have given $50 million — the largest single gift ever to breast cancer research
- Steve Madden Started His Shoe Business in 1990 With Just $1,100; 30 Years Later, His Brand Was Selling More Than $1 Billion in Merchandise Annually